A5080354461- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- HER2/EGFR in Cancer Research
- Statistical Methods in Clinical Trials
- Economic and Financial Impacts of Cancer
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Head and Neck Cancer Studies
- Colorectal Cancer Treatments and Studies
- BRCA gene mutations in cancer
- Medical Imaging Techniques and Applications
- Pancreatic and Hepatic Oncology Research
- Lymphoma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Global Cancer Incidence and Screening
- Advances in Oncology and Radiotherapy
- Estrogen and related hormone effects
- Gene expression and cancer classification
- Cancer Cells and Metastasis
European Organisation for Research and Treatment of Cancer
2015-2024
European Organisation for Research and Treatment of Cancer
2010-2020
Radboud University Nijmegen
2008-2019
The Netherlands Cancer Institute
2006-2019
Rijnstate Hospital
2009-2019
UCSF Helen Diller Family Comprehensive Cancer Center
2018
The University of Texas MD Anderson Cancer Center
2018
UC Davis Comprehensive Cancer Center
2012-2018
Institut Gustave Roussy
2007-2018
Champalimaud Foundation
2011-2018
The 70-gene signature test (MammaPrint) has been shown to improve prediction of clinical outcome in women with early-stage breast cancer. We sought provide prospective evidence the utility addition standard clinical–pathological criteria selecting patients for adjuvant chemotherapy.
A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal validate the an independent group of patients.Patients (n = 307, 137 events after a median follow-up 13.6 years) from five European centers were divided into high- and low-risk groups based on gene classification clinical risk classifications. Patients assigned if their 5-year distant metastasis-free survival probability as estimated by greater than 90%. clinicopathologic...
The European Organisation for Research and Treatment of Cancer conducted a randomized trial investigating the role radiotherapy (RT) after local excision (LE) ductal carcinoma-in-situ (DCIS) breast. We analyzed efficacy RT with 10 years follow-up on both overall risk recurrence (LR) related to clinical, histologic, treatment factors.After complete LE, women DCIS were randomly assigned no further or (50 Gy). One thousand ten mostly (71%) mammographically detected included. median was 10.5...
This phase III randomized open-label clinical trial was designed to evaluate the efficacy and safety of steroidal aromatase inactivator exemestane versus antiestrogen tamoxifen as first-line treatment for metastatic breast cancer (MBC) in postmenopausal women.The study conducted at 81 centers enrolled patients with measurable hormone-sensitive or locally advanced cancer. Prior adjuvant chemotherapy and/or were allowed. One previous regimen no prior hormone therapy disease permitted. Patients...
BackgroundBoth induction chemotherapy followed by irradiation and concurrent radiotherapy have been reported as valuable alternatives to total laryngectomy in patients with advanced larynx or hypopharynx cancer. We report results of the randomized phase 3 trial 24954 from European Organization for Research Treatment Cancer.
The emergence of the precision medicine paradigm in oncology has led to increasing interest integration real-world data (RWD) into cancer clinical research. As sources evidence (RWE), such could potentially help address uncertainties that surround adoption novel anticancer therapies clinic following their investigation trials. At present, RWE-generating studies which investigate antitumour interventions seem primarily focus on collecting and analysing observational RWD, typically forgoing...
The randomized EORTC 10981-22023 AMAROS trial investigates whether breast cancer patients with a tumor-positive sentinel node biopsy (SNB) are best treated an axillary lymph dissection (ALND) or radiotherapy (ART). aim of the current substudy was to evaluate identification rate and nodal involvement.The first 2,000 participating in were evaluated. Associations between technical, patient-, tumor-related factors outcome SNB procedure potential further involvement assessed.In 65 patients, could...
New effective chemotherapy is needed to improve the outcome of patients with advanced non-small-cell lung cancer (NSCLC). Paclitaxel administered as a single agent or in combination cisplatin has been shown be potentially new useful for treatment NSCLC.Between January 1995 and April 1996, 414 stage IIIB IV NSCLC were randomized received either control arm high-dose (100 mg/m(2)) paclitaxel (175 mg/m(2), 3-hour infusion) (80 every 21 days.Compared cisplatin-only arm, there was 9% improvement...